These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1832202)

  • 1. Pergolide: a dopamine agonist at both D1 and D2 receptors.
    Fuller RW; Clemens JA
    Life Sci; 1991; 49(13):925-30. PubMed ID: 1832202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
    Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
    Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum.
    De Keyser J; De Backer JP; Wilczak N; Herroelen L
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1147-54. PubMed ID: 8787038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans.
    O'Neill BV; Croft RJ; Leung S; Guille V; Galloway M; Phan KL; Nathan PJ
    Psychopharmacology (Berl); 2006 Sep; 188(1):92-9. PubMed ID: 16896953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
    Perachon S; Schwartz JC; Sokoloff P
    Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
    Zhang XX; Jin GZ; Wei YF
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):423-7. PubMed ID: 8701759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of specific D-1 and D-2 dopamine agonists (LY141865 and SKF-38393) and pergolide on urinary output of rats.
    Leander JD
    Arch Int Pharmacodyn Ther; 1987 Oct; 289(2):290-5. PubMed ID: 2962555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites.
    Wong DT; Threlkeld PG; Bymaster FP
    Arzneimittelforschung; 1993 Apr; 43(4):409-12. PubMed ID: 7684223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography.
    Trugman JM; Arnold WS; Touchet N; Wooten GF
    J Pharmacol Exp Ther; 1989 Sep; 250(3):1156-60. PubMed ID: 2674418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.
    Clemens JA; Okimura T; Smalstig EB
    Arzneimittelforschung; 1993 Mar; 43(3):281-6. PubMed ID: 8489554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
    Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M
    Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum.
    Fuxe K; O'Connor WT; Antonelli T; Osborne PG; Tanganelli S; Agnati LF; Ungerstedt U
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5591-5. PubMed ID: 1535159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice.
    Ralph-Williams RJ; Lehmann-Masten V; Geyer MA
    Neuropsychopharmacology; 2003 Jan; 28(1):108-18. PubMed ID: 12496946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive interaction between alpha-1 adrenergic and dopamine-2 receptors in locomotor activity of normo and supersensitive mice.
    Rubinstein M; Schinder AF; Gershanik O; Stefano FJ
    Life Sci; 1989; 44(5):337-46. PubMed ID: 2536881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.
    Bartholomeusz CF; Box G; Van Rooy C; Nathan PJ
    J Psychopharmacol; 2003 Mar; 17(1):9-15. PubMed ID: 12680735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors.
    Reid MS; O'Connor WT; Herrera-Marschitz M; Ungerstedt U
    Brain Res; 1990 Jun; 519(1-2):255-60. PubMed ID: 1975763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D1 dopamine receptor activity of anti-parkinsonian drugs.
    Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
    Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.